EMCURE

completes full acquisition of Zuventus Healthcare💊

acquired the remaining 20.42% equity shares from individual shareholders, making Zuventus a 100% subsidiary 🎯. Earlier, Emcure already held 79.58%, and this move strengthens its complete control over Zuventus. Zuventus specializes in pharmaceutical medicaments across various types and applications, while Emcure continues to lead in developing, manufacturing, and globally marketing a broad range of healthcare products 🌍✨. This strategic step reinforces Emcure’s vision of expanding its footprint in the pharmaceutical sector 💪.